Arrowhead Research said this week that its preclinical hepatitis B treatment ARC-520 was found to trigger a greater than 90 percent reduction in circulating HBV DNA in a chimpanzee chronically infected with the virus.

The chimpanzee has been infected for more than 30 years and has high viral-titer and antigenemia and nearly 100 percent of hepatocytes stain positive for HBV, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.